Mirati Therapeutics / Credit: AP Images

Mi­rati team demon­strates that their KRAS G12C drug is ac­tive in NSCLC — but how do they stack up next to Am­gen?

We have our­selves a horse race to watch in KRAS G12C, but it’s go­ing to be aw­ful­ly hard to call at this very ear­ly stage …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.